Full-Time

Sr. Specialist/ Manager

People

Confirmed live in the last 24 hours

Scribe Therapeutics

Scribe Therapeutics

51-200 employees

Develops CRISPR-based genetic medicine solutions

No salary listed

Senior, Expert

Alameda, CA, USA

This is an onsite role at our headquarters in Alameda, CA.

Category
Human Resources
People & HR
Requirements
  • Bachelor’s degree in HR Resources Management (or related field) is highly preferred. Graduate degree is a plus.
  • 6+ years (Manager) or 4+ years (Senior Specialist) of experience working in a professional work environment, preferably in the life sciences industry, with a proven track record of hands-on experience developing HR practices.
  • Strong understanding of People Operations/HR processes and programs.
  • Strong consultative style with proven experience supporting all levels of employees and management.
  • Proven customer-centric focus: ability to influence culture and create alignment between business goals, behaviors, and HR systems that drive performance and improve the employee experience.
  • Expertise in systems including ADP or TriNet, G Suite, Microsoft Suite, and the demonstrated ability to learn and adapt to new technology.
  • Ability to create and develop systems/processes with minimal current practices and policy to work from.
  • Ability to work both independently and collaboratively in a fast-paced, interdisciplinary team.
  • Proven planning and organizational skills, attention to detail, ability to handle multiple tasks.
  • Results-driven and comfortable working in a fast moving and constantly changing company, navigating through ambiguous scenarios in order to find effective solutions with the ability to work independently.
Responsibilities
  • Provides superior organizational skills, discipline and pragmatic hands-on guidance to the HR function and organization in People (HR) policy, compliance, planning, employee relations, practices and procedures for managers, teams and individual employees that further the mission, values and strategic vision of the business.
  • Responsible for day-to-day operations (new hires, benefit enrollment changes and terminations), benefits, and compliance with federal and state laws and regulations. This includes maintaining and keeping personnel files current and audit ready, including accuracy and maintenance and processing terminations.
  • Continuously refining and facilitating an innovative, and welcoming new employee orientation and first-day experience for new team members.
  • Responsible for coordination of mandated training, benefits enrollment, and new hire requests.
  • Work in partnership with the Director/Senior Director, People, work to define and develop requirements, and implement tools to support the People Team (HR).
  • Responsible for assisting and driving various Human Resources projects and actively participates in all other Human Resources initiatives and programs as appropriate, and hands-on with the implementation of new processes and systems.
  • Maintain and stay up to date on the knowledge and understanding of existing and proposed federal and state laws/regulations affecting human resource management.
  • Identify trends that could affect organizational objectives and/or operational resources.
  • Interpret appropriate laws and policies and apprise and advise management, employees and retirees accordingly.
  • Effectively collaborate with members within a fully integrated team to facilitate execution on projects within established timelines.
  • Foster a driven, fast-paced, dynamic, and fun environment in which to do rigorous science.
Desired Qualifications
  • Experience in systems such as TriNet, Lattice, Greenhouse, etc
  • Understanding of employment law and other government compliance regulations (i.e. Workers Comp, FLSA, FMLA, etc.)

Scribe Therapeutics focuses on genetic medicine by utilizing CRISPR technology to develop solutions for genetic diseases. CRISPR acts like molecular scissors that can cut and edit DNA, allowing for the potential correction of genetic defects. The company collaborates with healthcare providers, research institutions, and pharmaceutical companies to create and license its gene therapy platform. Scribe Therapeutics is also working on advanced delivery methods to enable in vivo genetic medicine, which involves editing genes directly within the body. Their technology is designed for high precision, allowing for targeted treatments of specific gene variants associated with genetic diseases. The goal of Scribe Therapeutics is to advance the field of genetic medicine and provide effective therapies for genetic disorders.

Company Size

51-200

Company Stage

Series B

Total Funding

$136.2M

Headquarters

Alameda, California

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • Scribe's partnership with Prevail includes $75 million upfront and $1.5 billion milestones.
  • The expanded Sanofi partnership, valued at $1.2 billion, boosts Scribe's market influence.
  • Experienced leadership with Dr. Aarif Khakoo and Dr. Maria Mirotsou enhances R&D efforts.

What critics are saying

  • Competition from Beam Therapeutics may impact Scribe's market share.
  • Legal disputes over CRISPR patents could pose challenges for Scribe's technologies.
  • Regulatory scrutiny on gene editing may delay Scribe's product development timelines.

What makes Scribe Therapeutics unique

  • Scribe's XE platform achieves over 75% editing efficiency in non-human primates' liver cells.
  • The company offers novel epigenetic editing capabilities with enhanced specificity and potency.
  • Scribe's proprietary CRISPR by Design platform enables precise allele-specific targeting.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

4%

2 year growth

12%
Business Wire
Mar 7th, 2025
Scribe Therapeutics Presents Data on its Epigenetic Long-Term X-Repressor Technology at the 2025 Keystone Symposia on Precision Genome Engineering Conference

Scribe Therapeutics presents data on its Epigenetic Long-Term X-Repressor technology at the 2025 Keystone Symposia on Precision Genome Engineering conference.

Business Wire
Jan 9th, 2025
Scribe Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Scribe Therapeutics to present at the 43rd Annual J.P. Morgan Healthcare Conference.

Business Wire
May 10th, 2024
Scribe Therapeutics Presents Data Demonstrating Highly Potent Gene Editing In Vivo, Including Saturated Editing Of Hepatocytes In Nhps, By An Engineered Xe Genome Editor; Showcases Novel Epigenetic Editing Capabilities At 2024 Asgct Annual Meeting

ALAMEDA, Calif.--(BUSINESS WIRE)--Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, presented data on its X-Editor (XE) and Epigenetic Long-Term X-Repressor (ELXR) technologies at the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting taking place in Baltimore, MD, and virtually.The data described in the company’s oral presentations and poster session showcase the dramatic potency, safety, and specificity of the novel XE genome editing and ELXR epigenetic editing platforms and the company's developments in successfully advancing these technologies into large animal models, including non-human primates.“ A major challenge in the field has been to achieve saturating levels of genome editing, at therapeutically relevant doses, with molecules that have better safety and delivery characteristics than CRISPR-Cas9—this has not been possible to date,” said Benjamin Oakes, Ph.D., co-founder and Chief Executive Officer of Scribe. “ For the first time, Scribe has demonstrated that the holistic engineering of a wholly unique and highly potent CRISPR enzyme can enable this goal. We have demonstrated that our XE platform can achieve editing rates of greater than 75% in the liver of NHPs, theoretically targeting all hepatocytes, while not displaying any detectable off-target effects in primary human cells.”“ Furthermore, we were thrilled to unveil a taste of the engineering behind Scribe’s ELXR epigenetic editing platform and present data elucidating the effectiveness of our comprehensive engineering approach compared to previous methodologies,” Dr. Oakes said. “ We believe this positions Scribe as the only company to have engineered, from the ground up, novel CRISPR genome editing and epigenetic editing platforms that can meet and often exceed the field’s expectations regarding therapeutically relevant potency and specificity.”Additional highlights on the developments of the XE platform and application in vivo include:Presentation: Engineering CasX to Create a Gene Editor with Potent Activity in Non-Human PrimatesUsing a variety of holistic engineering approaches, Scribe has created X-Editor molecules that are >100 steps in sequence space removed and >100-fold more potent than the naturally occurring CRISPR predecessorsXE achieves at or near-saturating levels of editing across a broad range of tissue types, including the eye, CNS, cardiac and skeletal muscle, and liver using either AAV or LNPXE is highly potent in non-human primate studies, achieving >75% editing in the liver and saturating editing at <1.5mg/kgWhen tested at different sites, XE is highly specific, demonstrating no detectable off-target editing at doses 10-fold higher than the effective dose in primary human hepatocytesScribe continues to expand the XE platform by engineering molecules with customizable genomic targetability by modifying the PAM recognition of the XE platformPresentation: AAV-Mediated Delivery of a Novel CasX-Editor Molecule Achieves Allele-Specific and Potent Editing of P23H Rhodopsin in a Mouse Model of Retinitis PigmentosaXE and AAV cargo engineering enables safe and selective XE delivery and editing in rod photoreceptors when administered subretinallyScribe demonstrates for the first time the use of XE to achieve allele-specific editing of the P23H.RHO locus, in an in vitro system and a phenotypically relevant in vivo model

Business Wire
Apr 22nd, 2024
Scribe Therapeutics To Present On Advances In Crispr Genome And Epigenome Editing At The 2024 American Society Of Gene Cell Therapy (Asgct) Annual Meeting

ALAMEDA, Calif.--(BUSINESS WIRE)--Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced its participation in the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place at the Baltimore Convention Center in Baltimore, MD, and virtually from May 7-11, 2024.Scribe will deliver two oral presentations and one poster presentation showcasing the latest developments in its CRISPR X-Editor (XE) and Epigenetic Long-Term X-Repressors (ELXR) technologies enabled by its CRISPR by Design™ approach. The company’s presentations will include data demonstrating the potent editing activity of XE in non-human primates, the potential for XE to address P23H.RHO-related autosomal dominant retinitis pigmentosa (adRP), and the comprehensive engineering approach to creating highly potent ELXRs.More details on each presentation are listed below and the full abstracts are available on the ASGCT meeting website.Oral presentation title: AAV-Mediated Delivery of a Novel CasX-Editor Molecule Achieves Allele-Specific and Potent Editing of P23H Rhodopsin in a Mouse Model of Retinitis PigmentosaAbstract number: 180Session title: Ophthalmic and Auditory: Disease FocusDate: Thursday, May 9, 2024Time: 2:15 - 2:30 p.m. ETLocation: Room 318-323Speaker: Cécile Fortuny, Ph.D., Senior Scientist II at ScribeOral presentation title: Engineering CasX to Create a Gene Editor with Potent Activity in Non-Human PrimatesAbstract number: 155Session title: Gene Disruption and ExcisionDate: Thursday, May 9, 2024Time: 2:55 - 3:12 p.m. ETLocation: Ballroom 3Speaker: Addison Wright, Ph.D., Principal Scientist at ScribePoster title: Comprehensive Engineering of a CasX-Based Repressor to Create Highly Potent Epigenetic EditorsAbstract number: 1670Session title: Epigenetic Editing and RNA EditingDate: Friday, May 10, 2024Time: 12:00 - 7:00 p.m. ETLocation: Exhibit HallSpeaker: Jason Fernandes, Ph.D., Principal Scientist at ScribeAbout Scribe TherapeuticsScribe Therapeutics is revolutionizing the development of optimized in vivo CRISPR-based genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases

Neuro Central
Dec 20th, 2023
Scribe Therapeutics Appoints Dr. Aarif Khakoo as Chief Scientific Officer and Head of Research and Development, and Dr. Maria Mirotsou as Vice President of Discovery Biology

Scribe Therapeutics appoints Dr. Aarif Khakoo as Chief Scientific Officer and Head of Research and Development, and Dr. Maria Mirotsou as Vice President of Discovery Biology.